Introduction
The subject of quality control is, like politics and religion, one that arouses people's emotions and is thus not so openly discussed as it should be. I was asked to set up a Working Party of the Association of Clinical Biochemists' Scientific and Technical Committee three years ago with a defined brief to promote and encourage new activities in the areas of quality control and to promote discussion of the many aspects of the subject.
The meeting at the Middlesex Hospital is an attempt to fulfil these requirements and to report some of the work that has been undertaken in recent years. I hope that this meeting will be the first of many, leading to a greater awareness of the problems associated with quality control and thus to an improvement in standards of performance.
The following papers are shortened versions of those presented at the meeting.
A ward-based quality control scheme P. M. ZAREMBSKI, M. C. BATESON, AND P. D.
GRIFFrrHS Ninewells Hospital and Medical School, Dundee, UK Laboratory staff may be lulled into a false sense of security by apparently satisfactory performance in their daily systematic quality control (QC) arrangements and external QC schemes. The former usually involve the use of known 'unknowns' in a batch of assays and, in general, are indicators only of the analytical performance of that manufactured specimen. External QC schemes, although testing more than analytical performance, are too retrospective to be of value to current patients. Testing the quality of a laboratory's performance should cover all events from the collection of the sample right through to the delivery of the laboratory report to the appropriate clinician.
The scheme that is about to be described has been in use in Ninewells Hospital, Dundee, for over two years.
Method
Each day an inpatient, for whom a number of biochemical tests have been requested, is selected. Permission is obtained from both the patient and the doctor in charge of the patient to take a double quantity of blood. This blood is divided between two series of the appropriate containers. One set is despatched to the laboratory together with the clinician's request form by the usual route. The phlebotomist prepares a duplicate request form but changes the consultant's name to that of one of us (MCB) and adds to the clinical information the letters QC. This form with its set of samples is given to the medical laboratory scientific officer (MLSO), who assists the QC officer (PMZ) with the handling and follow-up of the specimens.
The clinician's request and the first series are dealt with as any other request received by the laboratory, that is, the request data are entered into the laboratory computer, the specimen(s) are analysed, the results are entered into the computer, a report is generated, and the report is returned to the requester.
The second set of samples have their initial processing carried out by the MLSO, who then delivers them with the form to Reception for onward passage to the benches and for data entry into the computer. The fact that the samples are QC specimens is unknown to the analyst at the bench.
The QC officer checks the progress of the work through a computer enquiry terminal and is able to detect early any discrepancies between the results from the two series of samples and, if these are significant, to take appropriate remedial action.
The QC report is returned by the standard procedure to the designated clinician, who notes on the report the time of receipt, after which he returns it to the QC officer.
Results
Regular meetings are held between the clinician and the QC officer to discuss any problems brought to light by the system.
The system has the following potential benefits: it has a simple overall strategy, 'it is sensitive to a variety of errors, it tests within-day precision, it uses fresh human material, the concentration of analytes may be very variable, it uses a real clinical situation, it avoids analysts' subconscious bias,
Since the total process is tested, it is not surprising that, since the inception of the scheme, errors have been detected at virtually every point in the pathway: sample taking, sample handling, data input, technical faults such as sample transposition, analysts, interpretation of results, and problems of transport (for example, up to four days between receipt of the twin reports).
A Although only a few examples of the errors detected have been given, regrettably others have been recorded. When it is considered that these errors arose from just one sample being tested each day, how many undetected errors arise from the 400-500 other samples processed each day?
The only conclusions permissible are that vigilance must be extreme, and there is no room for complacency about any laboratory's performance. B. MINTY Northwick Park Hospital. Harrow. Middlesex Problems of blood gas quality control pH/blood gas analysis is not always restricted to departments of Clinical Biochemistry. It is becoming increasingly popular for specialised departments, for example, intensive therapy units, to perform their own blood gas analysis, and there is a move away from a central service for the whole hospital with little or no communication between the staff performing the analyses.
There are many advantages to this decentralisatiorr, particularly in areas where results are required urgently to influence patient therapy. This becomes increasingly advantageous after normal working hours. A major disadvantage to this, however, is the differing standards existing regarding the maintenance and operation of these analysers, and it may be necessary to question the quality of the results obtained.
A recent study (Minty and Nunn, 1977) has supplied data on the levels of accuracy attained in a sample of 16 laboratories in the north-west region of the UK. The study involved the analysis of blood of known P02 and PC02 and serum of known pH. For P02 and PC02 there were three results outside the acceptable limits (Cotlove et al., 1970) and nine for pH. The laboratories visited in this survey were a mixture of central departments of clinical chemistry and peripheral clinical laboratories. The incidence of major errors did not indicate that the peripheral laboratories functioned any less satisfactorily than the clinical chemistry departments. Many of the errors appeared to be inherent in the operator rather than caused by malfunction of the apparatus. Despite the obvious need, only one laboratory in the survey made any attempt to control the quality of their results. The new generation of automated blood gas analysers are designed to enable unskilled operators to perform their own analyses with minimal technical help and, it is hoped, to produce more rapid and reliable results. A recent survey (Minty and Barrett, 1978) investigated the quality of results produced by 100 untrained operators using an automated blood gas analyser sited in an intensive therapy unit. When the results were analysed only one analyst had a value for P02 outside the acceptable limits of accuracy. Six analysts produced unacceptable errors for PC02 measurement and 35 were at fault in their determination of pH. This survey demonstrated that it would be reasonably easy to establish a large group of personnel who could perform the blood analysis with very little training and who could produce reliable results. However, quality control is essential in this situation where the only recognition of inaccuracy by the unskilled staff may be when the results do not fit their clinical impression.
Until recently the lack of quality control in this field has been attributed to the lack of suitable reference materials although a few laboratories, usually staffed by an enthusiast with special expertise in blood gas analysis, have been performing quality control for the last 10 years. Now that a need has been established, manufacturers are responding by producing quality control materials. There are three main methods for blood gas quality control available:
Tonometry
The most common and reliable tonometer is the model 237 manufactured by Instrumentation Laboratory. This instrument can equilibrate a sample of blood with a gas phase of known oxygen and carbon dioxide tensions at 37 % in 10 minutes and thus provides the only means at present of obtaining a sample of whole blood of known P02 and PC02 which can be analysed alongside patient samples. This makes tonometry the method of choice in most situations. One of the problems of establishing this as a method for quality control is, of course, the initial cost of the tonometer although this cost can be offset against the price of a continuous supply of commercially available control material. Although very little technical expertise is needed to use the tonometer, it is not ideal for unskilled operators to perform checks on instrumentation in decentralised areas, particularly out of normal working hours.
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Because of the problems of instability of whole blood it is not possible to prepare or buy a whole blood control of known pH. However, serum can be used as the next best alternative. Aliquots from a batch of frozen serum need to be equilibrated to a constant PC02 in a tonometer and can then be used to monitor the function of a pH electrode (Bird and Henderson, 1971) .
Equilibrated buffer solutions
The use of buffer solutions equilibrated with known oxygen and carbon dioxide tensions is now becoming very popular. They are commercially supplied as 2m! ampoules and are available at three different levels of P02, PC02, and pH. They have a shelf-life of one year. They must be stored at 25°C and mixed before use and can then be rapidly analysed by unskilled staff at any time. However, they have certain limitations. Because their composition is dissimilar to that of whole blood, particularly with reference to the lack of protein, they will be unlikely to detect errors in pH electrode function due to changes in the physiochemical properties of the glass electrode or in the liquid junction potential which are well known to be very sensitive to the presence of protein.
A further limitation is their markedly lower oxygen affinity compared with whole blood. This may lead to observations of error due to contamination which would not appear with whole blood samples.
This control material can be useful to check analysers for gross malfunction, particularly on an emergency basis, but should not replace tonometry as the method of choice.
3 Whole blood gas control This fairly new product marketed as Quantra by American Hospital Supplies, is also an equilibrated buffer but has the colour of whole blood and contains human red cells. It is also supplied in ampoules and is available at three different levels of values. It has a stability of two months at 4°C and needs to be warmed to 37°before analysis.
The manufacturers claim that their product will detect problems in electrode function not apparent with the equilibrated buffer ampoules, although this claim has yet to be further investigated.
A wise laboratory will not rely on only one method for quality control in this difficult field and should always remember that problems are not only restricted to the laboratory but can occur at any time from the request for the investigation until the report is acted upon.
Outliers in clinical chemistry quality control M. J. R. HEALY London School ofHygiene and Tropical Medicine
In a large quality control scheme such as the NQCS it is commonplace that some of the results submitted are so far from the majority of results that they have to be treated as outliers and are best omitted from calculations of means and standard deviations. A frequently used technique calculates a mean m and standard deviation s from the whole sample and then rejects as outliers readings outside m±ks, where k may be 2!-or 3. Unfortunately, it is possible for outliers so to inflate the value of s that they go undetected by this method.
An alternative is to use an estimate of standard deviation that does not use the readings in the tails of the sample. One such estimate can be obtained as follows: I Sort the sample readings into ascending order and trim (say) 5 % from each end.
2 Estimate s by a linear function of the sorted values in the trimmed sample, with weights in arithmetic progression (for example, for six values the estimate is (-5 xi -3 X2 -Xs +X4 +3 X5 +5 xe) multiplied by a numerical factor).
The mean m can be estimated from the trimmed sample, and outlier limits can now be set at m±ks, as before; ordinarily, any outliers detected will lie in the trimmed tails and will not affect the estimates.
This technique has been applied to five sets of fortnightly results from the NQCS. The quite large analytic method differences mean that methods must be treated separately, and this leads to small samples. The estimated SDs have therefore been pooled across occasions, allowing for any dependence of SD upon mean. With a value of k of 3'2, the number of outliers detected was quite large, averaging 2·4 % of all readings submitted with no great variability among analytes.
Many outliers can be classified as blunders, that is, reported values which the responsible laboratory would wish to amend if they were called to its attention. From the occurrence of multiple outliers on the same occasion, it is plain that many blunders are due to sample misidentification. Others are likely to result from transcription and arithmetic and other clerical errors.
The model of a normal distribution contaminated by a few outliers in the tails fits most of the NQCS data quite well, but there were sporadic cases of Quality control in clinical chemistry laboratories much longer-tailed distributions. These may represent a failure of quality as much in need of explanation as one or more frank outliers.
The supraregional assay service (SAS) and the quality control of hormone assays M. J. WHEELER St. Thomas's Hospital, London Circulation of samples, among the SAS laboratories, for hormone measurement showed poor agreement between the laboratories for many of the hormones measured, both protein and steroid. This resulted in the use of standardised reagents for measuring certain hormones, with an encouraging improvement in agreement between laboratories. This early informal circulation of samples starting in the autumn of 1973 has led to the formation of quality control laboratories for all the hormones offered by the SAS.
The initial impetus for standardisation has slowed, and diversification of reagents and methods has again developed, perhaps responsible for the continuing poor agreement between laboratories for certain hormone measurements.
As more quality control schemes have been set up, so the different methods of running them have increased, each being run as a separate activity from the others. A great deal of information has now accumulated from these schemes, and hopefully with the appointment of a quality control coordinator for the SAS, standardisation of the organisation of the quality control schemes, as well as a fruitful pooling of information, will now take place.
As a consequence of extra, limited DHSS funding, the quality control organisers have expanded their services to the production of kits and to the inclusion of non-SAS laboratories into the quality control schemes.
Already kits are available for LH and FSH measurement, and others are currently being developed for several protein and steroid hormones.
The expansion of the service to non-SAS laboratories has shown that some consistently perform better than their SAS colleagues. It may be that a region could be better served by directing its samples to one of the regional, non-SAS laboratories rather than to the overburdened SAS centres. Just reward for these laboratories can come only if regional quality control officers divert some of their activities to monitoring the standard of hormone measurement within their regions, and regional scientific officers appreciate the rewards for the region of adequate support of such laboratories.
Regional monitoring of hormone assays has even greater urgency as the SAS begins to devolve some assays, perhaps requiring laboratories to take on these assays. The SAS continues to offer the quality control schemes; it now becomes the responsibility of the region to utilise the resulting information to the best advantage.
Data on hormone measurement within our hospital laboratories have been accumulating steadily for the past four years. It is now time for someone to act upon this, both within the SAS and within the regions.
Planning and organisation of the Nuffield survey into factors affecting analytical performance, in clinical chemistry laboratories P. R. N. KIND 1 AND C. E. WILDE2 St. Thomas Hospital.r London, and Royal Infirmary, 2 Doncaster It has become apparent, using the National Quality Control Scheme ROMVIS (Running Overall Mean Variance Index Score) as a measure of performance, that while there has been a general tendency for improvement, some laboratories appear to continue to perform badly. This survey was initiated in an attempt to define the factors that affect analytical performance in clinical chemistry laboratories. It was made possible by a generous grant from the Nuffield Provincial Hospital Trust, a grant that the Royal College of Pathologists agreed to administer.
Nine members were appointed to the survey team": three chemical pathologists, three hospital biochemists, and three people representing the Institute of Medical Laboratory Sciences. A sample of 70 of the laboratories that were willing to participate were selected by computer to cover all grades of laboratory size and performance. Each laboratory was given a survey code number. A comprehensive questionnaire was compiled so that data on many aspects of laboratory work, equipment, staff, organisation, etc could be collected. Part of the questionnaire was completed by the laboratory staff before a visit by three members of the survey team. At this visit more detailed points in the questionnaire were covered. A means of subjective scoring was devised to account for impressions gained on the visits, particularly in relation to organisation, quality control awareness, and the management contribution of different grades of staff. It was, from the start, intended to relate all the data collected to the NQCS ROMVIS, coded anonymously in the Birmingham computer. This index of performance would be used to determine which laboratory characteristics, if any, were particularly related to good or bad performance.
We were concerned that there were other indices of performance that might be used for this purpose. Such a series of indices can be derived from the results of the Wellcome reagent quality control survey, a survey that is also widely used in the United Kingdom. til order to compare these indices with the NQCS ROMVIS, laboratories taking part in the Wellcome scheme were asked to forward their end-of-period report confidentially by code number to the secretary of the project. Forty laboratories did so.
In addition to the Wellcome ranking (league position), which is based on the precision of all the analyses performed in the scheme, further performance indices were calculated. These were based on precision for all the analyses attempted (P30IS), on precision for the same 15 analyses performed on the NQCS (Pl5IS), on bias for all analyses (B30IS), and on bias for 15 analyses (BlsIS). An additional index was derived for precision by omitting enzyme results from the calculation.
The mean ROMVIS for each laboratory was calculated for the same six-month period covered by the Wellcome reports. This mean ROMVIS correlated well with the Wellcome ranking (p <0,(01) and with the Pl5IS (p <0'(01). The relationship was also significant with the P30lS (p <0'01) although it was better when enzymes were omitted (p <0,(01). There was no significant association with the bias indices.
Although it was clear that there were exceptions to the general pattern there did appear to be a significant correlation between Wellcome precision indices and the NQCS ROMVIS. We therefore assumed that either might be used as a valid measure of performance. The report using these indices to identify laboratory characteristics that affect performance is to be presented to the Nuffield Provincial Hospital Trust and the Royal College of Pathologists early in 1979. It is expected that the report will then be made widely available.
Spectrophotometer quality control:
A report of a national survey Quality control of analytical work is most frequently assessed by looking at the results of an assay. However, each component of the assay contributes to the overall performance, and each part of the assay can be assessed separately to measure its contribution to the overall imprecision. A manual method consists of four or five stages. Stevens and Randall (1977) have shown the contribution of each of these stages to the overall imprecision to be as follows: Automation has eliminated the errors contributed by the preparation stages with the result that the photometry error is now of greater significance in automated methods. In order to investigate the part played by photometric error in the assay, ampoules of cobalt chloride solution were distributed to the participants in the National Quality Control Scheme. Participants were asked to determine the two wavelengths of maximum absorbance and also to record the absorbances at these maxima.
The returned data were analysed in respect of the different instruments, and the results are shown in Tables 1-5. It can be seen that there is little difficulty in finding the wavelengths of maximum absorption but that many machines gave a poor measurement of the absorbance value. This performance applied equally to all makes of spectrophotometer, and we were sufficiently concerned to encourage manufacturers to help users recalibrate their machines. Subsequently, we received reports that some manufacturers had to replace some of the worst machines. The National Quality Control Advisory Panel for Chemical Pathology cooperation with the organisers of quality control schemes to suggest ways in which the assessment of laboratory performance can be improved.
The Panel defined its initial objectives as: 1 to identify the characteristics of poor performance, 2 to prepare a working classification of poor performance, 3 to suggest triggers for review by the Panel, and 4 to specify the nature of the review.
We had available, from the National Quality Control Scheme (NQCS), anonymous data from a number of good and poor laboratories, and we were able to examine a variety of situations in which individual laboratories exhibited poor performance overall or poor performance of individual methods.
We noted that poorly performing laboratories 1 contributed less frequently than most, 2 did not perform all determinations on each sample distributed, 3 used methods that were often difficult to classify, 4 obtained poor precision, and 5 usually had long-term problems but could on occasions exhibit a rapidly deteriorating situation.
The mechanisms generating a review have brought about 70 laboratories to the attention of the Panel. Of these, the vast majority were reviewed because of irregular contribution to the NQCS. The Panel attaches great importance to regular participation. The Panel has sent letters to about 30 laboratories. We have suggested visits to a small number and are awaiting the opportunity to visit them and to learn of their problems at first hand. Not all laboratories participate in the NQCS, and at the moment the only opportunity for us to assess performance is through the NQCS.
Meetings have been held with the organisers of the NQCS and the Pregnancy Urinary Oestrogens Quality Control Scheme to discuss common problems and the smooth coordination of the activities of the Panel and the schemes. The concern over the wide ranging performance of spectrophotometers has led us to arrange a second survey testing linearity as well as accuracy" and also to carry out checks on fixed wavelength spectrophotometers being used for enzyme assay at 340nin. It is suggested that regular quality control checks on spectrophotometers should be carried out by all users, and hopefully an annual survey may be possible.
The Panelj was established in May 1977 following proposals by the Joint Working Party on Quality Control (now the Joint Working Group on Quality Control). It has met on nine occasions since then.
The brief of the Panel is to help to improve the performance of chemical pathology laboratories through existing external quality control schemes, firstly by identifying poor performance and suggesting ways of improvement and, secondly, by close What shall we do with bad clinical biochemists? D. N. BARON Royal Free Hospital, London I use the term clinical biochemist to mean either a medical graduate or a science graduate who is in charge of a department.
The feeling of those who were responsible five years ago for setting up both the Working Group on Quality Control and, through the Working Group, the Quality Control Advisory Panels (whose functions are primarily educational) was that unless the professions put their own house in order someone else would try to do it for them. The medical and allied professions in the United Kingdom have always been extremely reluctant to set up any system of self-auditing. The attitude has always been, 'I have been appointed as a consultant cardiologist (or a top-grade hospital biochemist, or a reader in obstetrics, etc) and you must now let me get on with my work as best I can. I automatically will maintain my intelligence, integrity, mental and physical health, industriousness, and skills and keep up to date for the 30 years between my appointment and my retirement; and you have no right to suggest that there can be any diminution in the quantity and quality of my work'. But we are not working in a vacuum for our own benefit; we are paid by the public. Therefore the public have a duty and a right, which they are increasingly willing to use through political and other organisations, to see that they get their money's worth. If a laboratory continually has bad results in quality control then this laboratory is not doing its duty to the public, which is supporting it, and is not providing its contribution to health care. The responsibility rests with the clinical biochemist, and the common cause of poor results is an increase of work beyond the capabilities of the laboratory in terms of staff, space, and equipment. I assume that the Quality Control Advisory Panel are satisfied that the cause of the problem is not the deficiency of these capabilities, or that if these are deficient the clinical biochemist has made no effort to have these improved through the usual channels, or that if this has been rejected he has not asked for support from his clinical colleagues in getting the deficiencies remedied, or he has made no attempt to restrict the workload. So we have the laboratory with poor performance that does not improve after advice from the Panel. Or it could be that the clinical biochemist removes the laboratory from the quality control scheme as soon as bad results are received or a visit from the Panel is proposed. Or it could be that the laboratory does not take part in the National Scheme so that it is not possible for there to be any national professional check. Now it may well be that this laboratory has excellent external quality control with regional or Wellcome or American schemes, but we have no way of knowing; and all the relevant professions agreed to setting up the present system because we felt that someone ought to have a way of knowing. So far, we trust our laboratories not to send on their samples to a larger good laboratory and then to send these results back as their own; or to treat them as special and non-routine.
Quality control in clinical chemistry laboratories
Is the inadequacy of the clinical biochemist due to illness, or golf, or alchohol, or failure to keep up to date, or private practice, or failure to supervise junior staff? Diagnosis of inadequacy because of running a laboratory that performs poorly on quality control is a very limited approach. The inadequacy may well have been recognised by the rest of the staff, but what powers have local colleagues? The 'Three Wise Men' can advise and warn. The National Quality Control Scheme has begun to look at methods for testing interpretation as well as analysis. We do not yet have any working method of testing general up-to-date knowledge of the subject. The American Society of Clinical Pathology has a popular scheme in which multiple-choice questions, etc are available for pathologists (including non-medicals) of all disciplines. The results go back only to the person who took the test. The Royal College of Pathologists is looking into the question, and the Royal College of Physicians is working on a similar scheme. Would pathologists in general or clinical biochemists in particular consent to doing such a test if the result were to be known to any sort of assessors, whether from the professional organisations or from the DHSS? I very much doubt it. I am very keen that we should set up such an audit on a voluntary and self-testing basis. The Americans are even talking about retaking the Specialist Board examinations every five to 10 years! So at the moment we have only the reports of the quality control panels and no self-assessment. Let us assume that. we find a few bad clinical biochemists (as defined). We must have active discussion. In my view the responsibility next is that of the Area Medical Officer, and it is up to this person, who is eventually responsible for the health of all the people in the Area and is probably responsible for the employment of the relevant Health Service staff, to think what can be done to safeguard the patient for whom the laboratory, headed by the bad clinical biochemist, sends out the wrong results. Perhaps we should first ensure that the clincial biochemist attends appropriate educational courses. If the quality control still does not improve, or if the errant clinical biochemist refuses to go on courses, then I think our responsibility to our profession, to the patients, and to the public will require us to accept that the matter will have to be taken further. Should the clinical biochemist be seconded to a large laboratory for a period? There is no money these days to supplement the staff with an active member of the same seniority, so should one be thinking of early retirement?
The last question is, 'Who is responsible for telling the Area Medical Officer?' if such a course of action were agreed. At the moment I happen to be chair-holder of the working group to which the advisory panels report, made up of representatives of all the appropriate professional bodies. The problem may arise in the next year. I do not seek the responsibility nor wish to commit my successors.
another serum preparation from the same manufacturer was analysed (Fig. 2) . The inhomogeneity was in this case also obvious from the results of some other constituents (Table 1) . The inhomogeneity has been admitted by the manufacturer: the material contained bottles from two different batches based on the same bulk serum. The sera of another manufacturer gave difficulties in regard to urea only. The material probably contains an inhibitor of urease, causing too low urea values when small amounts of urease are used, which are normally sufficient. Methods using urease had an abnormally high coefficient of variation; these values were normal for methods using diacetylmonoxime. Figure 3 shows potassium results of a very inhomogenous serum preparation, consisting of three populations. The inhomogeneity was further reflected only in creatinine results, with a CV of 16'0% (normally 5'9-8'1 %); the CV for sodium results seemed quite normal (l'5 %). However, when the results were divided into three populations on the basis of the potassium concentrations, the mean sodium value of group 3 differed significantly from those of groups 2 and 1 ( Table 2) . As the mean NajCI ratios did not show significant differences, 
Reliability of control sera
Presuppositions for the use of test materials for external as well as internal quality control are homogeneity and stability of the material. Now most of these materials are of commercial origin and in a lyophilised condition. In the National Dutch Quality Control Scheme we were confronted three times in the course of two years with unacceptable test serum preparations obtained from different manufacturers.
In Fig. 1 the normal picture for the frequency distribution of potassium is given. In the same trial, Table 2 Sodium values in an inhomogenous serum and Na/Cl ratios in this serum Lyophilised sera are liable to errors in the filling and Iyophilisation procedure. Most manufacturers claim a filling precision of 0'1 % (51l1 per 5 ml).
Differences in water content of the dry material in the various vials are more difficult to measure, but this error might also be very small, about 0'1 %.
The most serious contribution to specimen variations is caused by differences in the amount of dry material caused by losses of dry material during freeze-elevated sodium values are always accompanied by elevated chloride values. This effect might be caused by irregular filling of vials, though the differences in potassium results cannot be caused by bad filling precision.
Potassium A-serum trial 25 60 70 drying. One manufacturer estimates this error at 0·5 %. Including a 0'3 % pipetting error, the total error due to the manufacturing process amounts to 0'6% at least (0·5 2+O·1 2+O·J2. 0'3 2)1, meaning that this type of error seriously contributes to the coefficient of variation found in external trials for sodium, potassium, and chloride determinations. Also, in testing reference methods, this manufacturing error seriously interferes with the total precision. In these cases the use of liquid sera might be recommended.
The third problem to be considered is the reliability of control sera for enzymes and the comparability of enzyme determinations at all. Youdenplots of enzyme determinations from our external control scheme (Figs. 4 and 5) show tremendous variation, though mainly of systematic character. Although it is difficult to prove, we had the impression that at least in one case a serum preparation was inhomogenous to creatine-kinase, probably due to instability of this enzyme. Comparing ratios of enzyme activity, 37 % of the participants deviated more than 30 %from the mean ratio. Normally this is less than 10% (see also Fig. 6 ). Moreover, several participants did not find any creatine-kinase activity at all, so the serum that did not contain y-GT activity either was considered unsuitable as a control serum for enzyme determinations in external and internal control programmes as well. Improvement in enzyme determinations may be attained in two ways: standardisation of methods or the use of enzyme standards.
We obtained a CV of 12-24 %for most enzyme determinations with standardisation of temperature only, results comparable with those of the German 'Ringversuche' in which completely standardised methods are used. Standardisation in Holland will meet with difficulties because of the individualistic temperament of Dutch. clinical chemists. Furthermore, inaccuracy in temperature measurements may be responsible for errors of between 5 and 10% in enzyme activities, though the precision of individual participants may be well within 5 %. Standardisation may inhibit progress. The use of enzyme standards or reference sera may be taken into consideration. We have good experience of the stability of lyophilised enzyme preparations in 1 % solutions. The problem with enzyme preparations as standards may be the isoenzyme effect that occurs even with standardised methods (Table 3) . Nevertheless we will investigate again the possibilities of enzyme standards as a means of getting acceptable results in external proficiency tests.
. It seems that isoenzymes of non-human origin give better results with standardised methods than with non-standardised ones (Table 4 ). Quality control in clinical chemistry laboratories Table 5 73
The stability of most components is indisputable as are the average values.
Returning to the reliability of control sera, in Table 5 an analysis of a Iyophilised serum over an I8-month period (stored at 4°C) is shown. 
